

"Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESMind Matters: Shining the spotlight on Alzheimer's Disease in India explores the rising prevalence of Alzheimer's disease in India, currently affecting 8.8 million people over age 60. It highlights diagnostic and management practices, comparing India's evolving healthcare infrastructure with Western standards. The paper discusses challenges in rural diagnosis, the role of PET scans, and the use of both modern and traditional treatments, including Ayurvedic herbs. It emphasizes the growing availability of disease-modifying therapies like Lecanemab and Donanemab, and the importance of early diagnosis—supported by innovations such as the Lumipulse blood test, now being locally manufactured in India.
The paper also outlines government initiatives like the National Mental Health Program, Ayushman Bharat Scheme, and Atal Vayo Abhyuday Yojna, aimed at improving elderly care and dementia management. India's potential in Alzheimer's clinical research is underscored by its large, genetically diverse, and treatment-naive population. Studies like TLSA and SANSCOG are paving the way for deeper epidemiological insights. The paper calls for more region-specific data, cost analyses, and caregiver support frameworks, noting the unique familial structures in India. Finally, it advocates for India's inclusion in global research consortia and highlights regulatory progress, such as the DCGI's push for local Phase III trials. With a growing pharmaceutical industry and English-speaking healthcare professionals, India is positioned to become a key player in Alzheimer's research and care.